NCT06229782 is a NA clinical trial of Orbital Doppler ultrasonography in Brain Death, sponsored by Korgün Ökmen.

Who is sponsoring NCT06229782?

NCT06229782 is sponsored by Korgün Ökmen.

What drugs are being tested in NCT06229782?

Interventions in NCT06229782: Orbital Doppler ultrasonography, Transcranial Doppler ultrasonography, Computed Tomography Angiography.

What condition does NCT06229782 study?

NCT06229782 studies Brain Death.

Is NCT06229782 still recruiting?

NCT06229782 is currently completed. Last updated 30 January 2024.

Last reviewed 2024-01-30 · How we verify

NCT06229782

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Orbital Artery Doppler Ultrasound in Brain Death

Completed NA Last updated 30 January 2024

What this trial tests

NA trial testing Orbital Doppler ultrasonography in Brain Death in 66 participants. Completed in 13 June 2022.

Timeline

11 January 2017

Primary endpoint
25 January 2022

13 June 2022

Quick facts

Lead sponsor	Korgün Ökmen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	66
Start date	11 January 2017
Primary completion	25 January 2022
Estimated completion	13 June 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Orbital Doppler ultrasonography
Transcranial Doppler ultrasonography
Computed Tomography Angiography

Conditions studied

Brain Death — all drugs for Brain Death →

Sponsor

Korgün Ökmen

Who can join

Adults 18 to 90, any sex, with Brain Death. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Brain death is the irreversible loss of all activity in the brain, brainstem, and cerebellum, the part of the central nervous system that remains inside the skull. The clinical diagnosis of brain death should be supported by ancillary tests that provide information about cerebral blood flow or electrical activity in the brain. Some of the ancillary tests that evaluate cerebral blood flow include transcranial Doppler ultrasonography (TDUS), computed tomography (CT) angiography (CTA), and catheter-based cerebral angiography. This study hypothesized that Orbital Doppler ultrasonography (ODUS) alone is more effective than TDUS in detecting intracranial blood flow in diagnosing brain death. To this end, the investigators examined the results of ODUS in patients diagnosed as brain dead who underwent CT angiography.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Brain Death

Currently open trials in the same condition.

NCT06640088 — Determining ICU Staffs Conceptions, Opinions, Views, Experiences and Reflection of Brain Death and Organ Donation · recruiting

Other Korgün Ökmen trials

Trials by the same sponsor.

NCT06965634 — Investigation of the Effectiveness of Lung Ultrasonography in Intraoperative Fluid Management · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06229782 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Korgün Ökmen
Last refreshed: 30 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06229782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing